Literature DB >> 11598267

A phosphatase associated with metastasis of colorectal cancer.

S Saha1, A Bardelli, P Buckhaults, V E Velculescu, C Rago, B St Croix, K E Romans, M A Choti, C Lengauer, K W Kinzler, B Vogelstein.   

Abstract

To gain insights into the molecular basis for metastasis, we compared the global gene expression profile of metastatic colorectal cancer with that of primary cancers, benign colorectal tumors, and normal colorectal epithelium. Among the genes identified, the PRL-3 protein tyrosine phosphatase gene was of particular interest. It was expressed at high levels in each of 18 cancer metastases studied but at lower levels in nonmetastatic tumors and normal colorectal epithelium. In 3 of 12 metastases examined, multiple copies of the PRL-3 gene were found within a small amplicon located at chromosome 8q24.3. These data suggest that the PRL-3 gene is important for colorectal cancer metastasis and provide a new therapeutic target for these intractable lesions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11598267     DOI: 10.1126/science.1065817

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  216 in total

1.  The cytosolic domain of protein-tyrosine kinase 7 (PTK7), generated from sequential cleavage by a disintegrin and metalloprotease 17 (ADAM17) and γ-secretase, enhances cell proliferation and migration in colon cancer cells.

Authors:  Hye-Won Na; Won-Sik Shin; Andreas Ludwig; Seung-Taek Lee
Journal:  J Biol Chem       Date:  2012-06-04       Impact factor: 5.157

2.  An anatomy of normal and malignant gene expression.

Authors:  Kathy Boon; Elisson C Osorio; Susan F Greenhut; Carl F Schaefer; Jennifer Shoemaker; Kornelia Polyak; Patrice J Morin; Kenneth H Buetow; Robert L Strausberg; Sandro J De Souza; Gregory J Riggins
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-15       Impact factor: 11.205

Review 3.  Protein kinase CK2: structure, regulation and role in cellular decisions of life and death.

Authors:  David W Litchfield
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

4.  Whole genome analysis of genetic alterations in small DNA samples using hyperbranched strand displacement amplification and array-CGH.

Authors:  José M Lage; John H Leamon; Tanja Pejovic; Stefan Hamann; Michelle Lacey; Deborah Dillon; Richard Segraves; Bettina Vossbrinck; Antonio González; Daniel Pinkel; Donna G Albertson; Jose Costa; Paul M Lizardi
Journal:  Genome Res       Date:  2003-02       Impact factor: 9.043

5.  Consequences of nonadaptive alterations in cancer.

Authors:  Alexander Kamb
Journal:  Mol Biol Cell       Date:  2003-02-21       Impact factor: 4.138

6.  CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.

Authors:  Matthew S Brown; Oumou T Diallo; Michael Hu; Reza Ehsanian; Xinping Yang; Pattatheyil Arun; Hai Lu; Vicci Korman; Gretchen Unger; Khalil Ahmed; Carter Van Waes; Zhong Chen
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

Review 7.  Is there a genetic signature for liver metastasis in colorectal cancer?

Authors:  Cristina Nadal; Joan Maurel; Pere Gascon
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

8.  15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.

Authors:  Min Yan; Ronald M Rerko; Petra Platzer; Dawn Dawson; Joseph Willis; Min Tong; Earl Lawrence; James Lutterbaugh; Shilong Lu; James K V Willson; Guangbin Luo; Jack Hensold; Hsin-Hsiung Tai; Keith Wilson; Sanford D Markowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-01       Impact factor: 11.205

9.  1H, 13C and 15N resonance assignments and secondary structure of the human protein tyrosine phosphatase, PRL-2.

Authors:  Hongjun Zhou; Marijo Gallina; Hongyuan Mao; Daniel Nietlispach; Stephen F Betz; Jacquelyn S Fetrow; Peter J Domaille
Journal:  J Biomol NMR       Date:  2003-12       Impact factor: 2.835

10.  PRL3-zumab, a first-in-class humanized antibody for cancer therapy.

Authors:  Min Thura; Abdul Qader Omer Al-Aidaroos; Wei Peng Yong; Koji Kono; Abhishek Gupta; You Bin Lin; Kousaku Mimura; Jean Paul Thiery; Boon Cher Goh; Patrick Tan; Ross Soo; Cheng William Hong; Lingzhi Wang; Suling Joyce Lin; Elya Chen; Sun Young Rha; Hyun Cheol Chung; Jie Li; Sayantani Nandi; Hiu Fung Yuen; Shu-Dong Zhang; Yeoh Khay Guan; Jimmy So; Qi Zeng
Journal:  JCI Insight       Date:  2016-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.